165 related articles for article (PubMed ID: 34792724)
1. An overview of current therapeutic strategies for glioblastoma and the role of CD73 as an alternative curative approach.
Arab S; Hasannejad F
Clin Transl Oncol; 2022 May; 24(5):742-756. PubMed ID: 34792724
[TBL] [Abstract][Full Text] [Related]
2. CD73 Promotes Glioblastoma Pathogenesis and Enhances Its Chemoresistance via A
Yan A; Joachims ML; Thompson LF; Miller AD; Canoll PD; Bynoe MS
J Neurosci; 2019 May; 39(22):4387-4402. PubMed ID: 30926752
[TBL] [Abstract][Full Text] [Related]
3. Nasal Administration of Cationic Nanoemulsions as CD73-siRNA Delivery System for Glioblastoma Treatment: a New Therapeutical Approach.
Azambuja JH; Schuh RS; Michels LR; Gelsleichter NE; Beckenkamp LR; Iser IC; Lenz GS; de Oliveira FH; Venturin G; Greggio S; daCosta JC; Wink MR; Sevigny J; Stefani MA; Battastini AMO; Teixeira HF; Braganhol E
Mol Neurobiol; 2020 Feb; 57(2):635-649. PubMed ID: 31407144
[TBL] [Abstract][Full Text] [Related]
4. CD73 on cancer-associated fibroblasts enhanced by the A
Yu M; Guo G; Huang L; Deng L; Chang CS; Achyut BR; Canning M; Xu N; Arbab AS; Bollag RJ; Rodriguez PC; Mellor AL; Shi H; Munn DH; Cui Y
Nat Commun; 2020 Jan; 11(1):515. PubMed ID: 31980601
[TBL] [Abstract][Full Text] [Related]
5. Methotrexate up-regulates ecto-5'-nucleotidase/CD73 and reduces the frequency of T lymphocytes in the glioblastoma microenvironment.
Figueiró F; de Oliveira CP; Bergamin LS; Rockenbach L; Mendes FB; Jandrey EH; Moritz CE; Pettenuzzo LF; Sévigny J; Guterres SS; Pohlmann AR; Battastini AM
Purinergic Signal; 2016 Jun; 12(2):303-12. PubMed ID: 26910734
[TBL] [Abstract][Full Text] [Related]
6. Involvement of CD73 and A2B Receptor in Radiation-Induced DNA Damage Response and Cell Migration in Human Glioblastoma A172 Cells.
Kitabatake K; Kaji T; Tsukimoto M
Biol Pharm Bull; 2021 Feb; 44(2):197-210. PubMed ID: 33268695
[TBL] [Abstract][Full Text] [Related]
7. Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma.
Goswami S; Walle T; Cornish AE; Basu S; Anandhan S; Fernandez I; Vence L; Blando J; Zhao H; Yadav SS; Ott M; Kong LY; Heimberger AB; de Groot J; Sepesi B; Overman M; Kopetz S; Allison JP; Pe'er D; Sharma P
Nat Med; 2020 Jan; 26(1):39-46. PubMed ID: 31873309
[TBL] [Abstract][Full Text] [Related]
8. CD73-positive extracellular vesicles promote glioblastoma immunosuppression by inhibiting T-cell clonal expansion.
Wang M; Jia J; Cui Y; Peng Y; Jiang Y
Cell Death Dis; 2021 Nov; 12(11):1065. PubMed ID: 34753903
[TBL] [Abstract][Full Text] [Related]
9. CD73 Downregulation Decreases In Vitro and In Vivo Glioblastoma Growth.
Azambuja JH; Gelsleichter NE; Beckenkamp LR; Iser IC; Fernandes MC; Figueiró F; Battastini AMO; Scholl JN; de Oliveira FH; Spanevello RM; Sévigny J; Wink MR; Stefani MA; Teixeira HF; Braganhol E
Mol Neurobiol; 2019 May; 56(5):3260-3279. PubMed ID: 30117104
[TBL] [Abstract][Full Text] [Related]
10. Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors.
Beavis PA; Divisekera U; Paget C; Chow MT; John LB; Devaud C; Dwyer K; Stagg J; Smyth MJ; Darcy PK
Proc Natl Acad Sci U S A; 2013 Sep; 110(36):14711-6. PubMed ID: 23964122
[TBL] [Abstract][Full Text] [Related]
11. 5'-ectonucleotidase mediates multiple-drug resistance in glioblastoma multiforme cells.
Quezada C; Garrido W; Oyarzún C; Fernández K; Segura R; Melo R; Casanello P; Sobrevia L; San Martín R
J Cell Physiol; 2013 Mar; 228(3):602-8. PubMed ID: 22833450
[TBL] [Abstract][Full Text] [Related]
12. CD73 in glioblastoma: Where are we now and what are the future directions?
Gelsleichter NE; Azambuja JH; Rubenich DS; Braganhol E
Immunol Lett; 2023; 256-257():20-27. PubMed ID: 36958430
[TBL] [Abstract][Full Text] [Related]
13. Elevated ecto-5'-nucleotidase-mediated increased renal adenosine signaling via A2B adenosine receptor contributes to chronic hypertension.
Zhang W; Zhang Y; Wang W; Dai Y; Ning C; Luo R; Sun K; Glover L; Grenz A; Sun H; Tao L; Zhang W; Colgan SP; Blackburn MR; Eltzschig HK; Kellems RE; Xia Y
Circ Res; 2013 May; 112(11):1466-78. PubMed ID: 23584256
[TBL] [Abstract][Full Text] [Related]
14. Targeting CD73 and downstream adenosine receptor signaling in triple-negative breast cancer.
Allard B; Turcotte M; Stagg J
Expert Opin Ther Targets; 2014 Aug; 18(8):863-81. PubMed ID: 24798880
[TBL] [Abstract][Full Text] [Related]
15. CD73 on B16F10 melanoma cells in CD73-deficient mice promotes tumor growth, angiogenesis, neovascularization, macrophage infiltration and metastasis.
Koszałka P; Gołuńska M; Stanisławowski M; Urban A; Stasiłojć G; Majewski M; Wierzbicki P; Składanowski AC; Bigda J
Int J Biochem Cell Biol; 2015 Dec; 69():1-10. PubMed ID: 26545615
[TBL] [Abstract][Full Text] [Related]
16. Blockade of CD73 delays glioblastoma growth by modulating the immune environment.
Azambuja JH; Schuh RS; Michels LR; Iser IC; Beckenkamp LR; Roliano GG; Lenz GS; Scholl JN; Sévigny J; Wink MR; Stefani MA; Battastini AMO; Figueiró F; Teixeira HF; Braganhol E
Cancer Immunol Immunother; 2020 Sep; 69(9):1801-1812. PubMed ID: 32350590
[TBL] [Abstract][Full Text] [Related]
17. The ectonucleotidases CD39 and CD73 on T cells: The new pillar of hematological malignancy.
Jiang X; Wu X; Xiao Y; Wang P; Zheng J; Wu X; Jin Z
Front Immunol; 2023; 14():1110325. PubMed ID: 36776866
[TBL] [Abstract][Full Text] [Related]
18. Influence of NSAIDs and methotrexate on CD73 expression and glioma cell growth.
Lopes DV; de Fraga Dias A; Silva LFL; Scholl JN; Sévigny J; Battastini AMO; Figueiró F
Purinergic Signal; 2021 Jun; 17(2):273-284. PubMed ID: 33745072
[TBL] [Abstract][Full Text] [Related]
19. Cervical cancer cells produce TGF-β1 through the CD73-adenosine pathway and maintain CD73 expression through the autocrine activity of TGF-β1.
García-Rocha R; Monroy-García A; Hernández-Montes J; Weiss-Steider B; Gutiérrez-Serrano V; Del Carmen Fuentes-Castañeda M; Ávila-Ibarra LR; Don-López CA; Torres-Pineda DB; de Lourdes Mora-García M
Cytokine; 2019 Jun; 118():71-79. PubMed ID: 30301599
[TBL] [Abstract][Full Text] [Related]
20. CD73 on T Cells Orchestrates Cardiac Wound Healing After Myocardial Infarction by Purinergic Metabolic Reprogramming.
Borg N; Alter C; Görldt N; Jacoby C; Ding Z; Steckel B; Quast C; Bönner F; Friebe D; Temme S; Flögel U; Schrader J
Circulation; 2017 Jul; 136(3):297-313. PubMed ID: 28432149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
